Drug intelligence / Profile preview

AC591

Development stage: Phase 2
Lead developer: Jiangsu Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

AC591 is an investigational herbal medicine being developed by Shandong New Time Pharmaceutical, part of the Lunan Pharmaceutical Group. It is a standardized extract of the Huangqi Guizhi Wuwu decoction, a traditional Chinese herbal formula. AC591 is formulated as granules and is under investigation for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) caused by agents such as paclitaxel and oxaliplatin. Clinical trials, including a Phase II study, are evaluating its efficacy in reducing neurotoxicity in cancer patients. Preclinical and clinical data suggest that AC591 may prevent neuropathy by modulating inflammation and immune responses, without compromising the antitumor activity of chemotherapy.

Other names: AC591 granulesAC-591 granulesAC 591 granulesAC591颗粒

Beyond the preview

Go deeper on AC591.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC591.

Explore the full profile